Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics


Xeris Pharmaceuticals, Inc. (XERS)

Today's Latest Price: $5.14 USD

0.21 (-3.93%)

Updated May 29 4:00pm

Add XERS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

XERS Stock Summary

  • Xeris Pharmaceuticals Inc's stock had its IPO on June 21, 2018, making it an older stock than just 4.25% of US equities in our set.
  • With a price/sales ratio of 47.18, Xeris Pharmaceuticals Inc has a higher such ratio than 96.26% of stocks in our set.
  • In terms of volatility of its share price, XERS is more volatile than 94.25% of stocks we're observing.
  • Stocks that are quantitatively similar to XERS, based on their financial statements, market capitalization, and price volatility, are SWAV, ASTC, NWBO, RIGL, and AKER.
  • XERS's SEC filings can be seen here. And to visit Xeris Pharmaceuticals Inc's official web site, go to www.xerispharma.com.
XERS Daily Price Range
XERS 52-Week Price Range

XERS Stock Price Chart More Charts


XERS Price/Volume Stats

Current price $5.14 52-week high $12.94
Prev. close $5.35 52-week low $1.42
Day low $4.90 Volume 416,015
Day high $5.28 Avg. volume 623,587
50-day MA $2.72 Dividend yield N/A
200-day MA $6.34 Market Cap 193.20M

Xeris Pharmaceuticals, Inc. (XERS) Company Bio


Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.


XERS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

XERS Latest Social Stream


Loading social stream, please wait...

View Full XERS Social Stream

Latest XERS News From Around the Web

Below are the latest news stories about Xeris Pharmaceuticals Inc that investors may wish to consider to help them evaluate XERS as an investment opportunity.

Company News for May 26, 2020

Companies In The News Are: TTWO, XERS, SPLK, NAVB

Yahoo | May 26, 2020

Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery.

Yahoo | May 22, 2020

The President of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), Paul Edick, Just Bought 32% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Xeris Pharmaceuticals, Inc. (NASDAQ:XERS...

Yahoo | May 14, 2020

Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke™ Outside the U.S on a Named Patient Basis

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced an exclusive agreement with Clinigen Group plc (AIM: CLIN, ‘Clinigen’) to manage the supply and distribution of Gvoke™ outside of the United States where Gvoke is not currently licensed.

Yahoo | May 14, 2020

Xeris Pharmaceuticals, Inc. (XERS) Q1 2020 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by, and welcome to the Xeris Pharmaceuticals First Quarter 2020 Financial Results Conference Call. Paul will provide opening remarks, and Barry will review the financial results, then we'll open the line for questions.

Yahoo | May 9, 2020

Read More 'XERS' Stories Here

XERS Price Returns

1-mo 93.96%
3-mo 44.38%
6-mo -42.44%
1-year -55.23%
3-year N/A
5-year N/A
YTD -27.09%
2019 -58.53%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching XERS

Want to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:

Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8921 seconds.